Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without Micropulse Laser for DME
NCT03690947Phase 4Completed
- Sponsor
- Beijing Hospital
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Best Corrected Visual Acuity changes at 12 months. Started Oct 2018; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03690947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690947.